Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies,” published in the February 2025 issue of American Journal of Hematology by Senapati et ...
February 14, 2025 – IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
IN8bio has announced encouraging new clinical data from its ongoing Phase I trial of INB-100, an allogeneic gamma-delta T ...
Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...
The Standard-Times on MSN2d
New Bedford family of toddler fighting leukemia gets support from Cops for Kids with CancerCops for Kids with Cancer seeks to remove the financial burden for families impacted by a cancer diagnosis. This week they ...
Moleculin Biotech (MBRX) has received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 ...
Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback